İntravitreal Enjeksiyon İğnesi Çapının Göz İçi Basıncına Etkisi

Amaç: İntravitreal enjeksiyon yapılan hastalarda enjeksiyon iğnesi çapının göz içi basıncına etkisiniincelemek amaçlanmıştır.Gereç ve Yöntemler: Diyabetik retinopati ve makula ödemi nedeniyle intravitreal aflibersept (IVA) enjeksiyonuuygulanan 107 hastanın 107 gözü çalışmaya dahil edildi. Yirmi altı gauge (G) iğne kullanılan52 hastanın 52 gözü Grup 1 olarak, 30 G iğne kullanılan 55 hastanın 55 gözü Grup 2 olarak değerlendirildi.Göz içi basıncı (GİB) blefarosta takılmadan önce (ÖGİB), blefarosta takıldıktan sonra (BGİB) veenjeksiyon sonrası 1. dakikada (EGİB) ölçüldü.Bulgular: Grup 1’de 25 erkek, 27 kadın, Grup 2’de 26 erkek, 29 kadın hasta mevcuttu (p=0,93). Yaş ortalamasıGrup 1’de 56,40±7,62 yıl, Grup 2’de 56,58±6,91 yıldı (p=0,90). Ortalama ÖGİB ve BGİB sırasıylaGrup 1’de 18,56±3,91 mmHg ve 21,94±4,27 mmHg, Grup 2’de 18,10±3,80 mmHg ve 20,63±4,91 mmHgidi; aradaki farklar istatistiksel olarak anlamlı değildi (sırasıyla, p=0,63 ve p=0,14). Ortalama EGİB değerleriise Grup 1’de 34,84±16,46 mmHg, Grup 2’de 47,05±10,02 mmHg olup aradaki fark istatistikselolarak anlamlıydı (p=0,001). EGİB–BGİB fark ortalaması Grup 1’de 12,86±17,63, Grup 2’de 25,87±9,95idi (p=0,001). EGİB–ÖGİB fark değerleri ortalaması ise Grup 1’de 15,80±16,65, Grup 2’de 28,25±10,09olarak tespit edildi (p=0,001) (Tablo 1).Tartışma ve Sonuç: Demografik benzerlikleri olan ve aynı intravitreal ilaçlar uygulanan hastalarda enjeksiyonun26 G iğne ile uygulanmasının 30 G iğne ile uygulanmasına göre daha az göz içi basıncıdeğişimi yaptığı görülmüştür.

Effects of Intravitreal Injection Needle Diameter on the Intraocular Pressure

Aim: This study aimed to investigate the effects of injection needle diameter on the intraocular pressure in patients who underwent intravitreal injection. Materials and Methods: One hundred and seven eyes of 107 patients who underwent intravitreal aflibercept (IVA) injection for diabetic retinopathy or macular edema were included. Fifty-two eyes of the 52 patients for whom a 26-gauge (G) needle was used were designated as Group 1 and 55 eyes of the 55 patients for whom a 30-G needle was used as Group 2. Intraocular pressure (IOP) was measured before (BIOP) and after (AIOP) the blepharostat placement (AIOP) and 1 minute after the injection (EIOP). Results: There were 25 males and 27 females in Group 1 and 26 males and 29 females in Group 2 (p=0.93). The mean age was 56.40±7.62 years for Group 1 and 56.58±6.91 years for Group 2 (p=0.90). The mean BIOP and AIOP were respectively 18.56±3.91 mmHg and 21.94±4.27 mmHg for Group 1 while 18.10±3.80 mmHg and 20.63±4.91 mmHg for Group 2; and the differences were not statistically significant (p=0.63 and p=0.14, respectively). The mean EIOP was 34.84±16.46 mmHg for Group 1 and 47.05±10.02 mmHg for Group 2; and the difference was statistically significant (p=0.001). The mean EIOP–AIOP and EIOP–BIOP differences were respectively 12.86±17.63 mmHg and 15.80±16.65 mmHg for Group 1 (p=0.001) and 25.87±9.95 mmHg and 28.25±10.09 mmHg for Group 2 (p=0.001). Discussion and Conclusion: It was seen that less fluctuation was caused in the intraocular pressure by use of a 26-G compared to a 30-G needle during the injection of the same intravitreal drugs in demographically similar patients.

PDF

___

Yannuzzi NA, Patel SN, Bhavsar KV ve ark. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158(2):319–27.
Pang CE, Mrejen S, Hoang QV ve ark. Association between needle size, postinjection reflux and intraocular pressure spikes after intravitreal injections. Retina. 2015;35(7):1401–6.
van Asten F, van Middendorp H, Verkerk S ve ark. Are Intravitreal injections with ultra thin 33 G needles less paınful than commonly used 30 G Needles? Retina. 2015;35(9):1778–85.
Güler M, Bilgin B, Çapkın M ve ark. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol. 2015;29(3):190–4.
Haas P, Falkner-Radler C, Wimpissinger B ve ark. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94(2):198–202.
El Chehab H, Agard E, Russo A ve ark. Intraocular pressure spikes after aflibercept intravitreal injections. Ophthalmologica. 2016;236(1):43–7.
Loureiro M, Matos R, Sepulveda P ve ark. Intravitreal injections of bevacizumab: the impact of needle size in intraocular pressure and pain. J Curr Glaucoma Pract. 2017;11(2):38–41
Chritoffersen T, Fors T, Ringberg U ve ark. Tonometry in the general practice setting (I): Tono-Pen compared to Goldmann applanation tonometry. Acta Ophthalmol. 1993;71:103–8.
Özdemir N, Tekin A, Ersöz TR ve ark. Tono-Pen tonometresi ile Goldmann applanasyon tonometresinin klinik olarak karşılaştırılması. MN Ophthalmology. 1997;4:168–70.
Satıcı A, Oğuz H, Gürler B. Göz içi basınç ölçümünde Goldmann aplanasyon tonometresi ile Tono-Pen ve nonkontakt tonometre değerlerinin karşılaştırılması. T Oft Gaz. 1997;27:321–4.
Whitacre MM, Stein R. Surces of error with use of Goldmann-type tonometers. Surv Ophthalmol. 1993;38:1–30.
Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25:661–72
Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol. 2010;248:1371–5.
Gismondi M, Salati C, Salvetat ML ve ark. Short term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18:658–61.
Kotliar K, Maier M, Bauer S ve ark. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777–81.
Sharei V, Höhn F, Köhler T ve ark. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20:174–9.
Bakri SJ, Pulido JS, McCannel CA ve ark. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23:181–5.
Wong LJ, Desai RU, Jain A ve ark. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 2008;28:1151–8.
Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56:95–113.
Alakuş MF, Taş M, Öner V ve ark. Diyabetik Maküla ödeminde intravitreal bevacizumab etkinliğininin değerlendirilmesi. Retina Vitreus. 2012;1:35–40.
Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond). 2012;26:1–16.